GSK reports Mo-Rez ovarian data as GSK stock costs EUR 22.67

Published on 10/24/2026 at 11:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

GSK reports updated ovarian cancer data from a phase Ib trial. GSK stock costs EUR 22.67 in weekend trading on October 24, 2026.

Weekend trading and pipeline data

GSK reported a 62 percent response rate for Mo-Rez on October 23, 2026.
GSK stock trades at EUR 22.67 at 10:56 a.m. CEST on October 24, 2026.
The next Xetra session is scheduled for October 26, 2026.

Moderne Pharma-Produktionsanlage mit Glasfassade und Laboren bei Dämmerlicht — GSK plc (ISIN GB0009252882) betreibt moderne Pharmaanlagen mit Laboren und Produktionshallen in der Abenddämmerung, Illustration mit AI erstellt.

GSK plc reported updated data from its phase I BEHOLD-1 trial for mocertatug rezetecan, or Mo-Rez, in platinum-resistant ovarian cancer on October 23, 2026, according to GSK. In the phase Ib trial, Mo-Rez achieved a confirmed objective response rate of 62 percent and a median duration of response of 12.2 months at the selected phase III dose.

At 10:56 a.m. CEST on October 24, 2026, GSK stock trades in weekend trading at Lang & Schwarz at EUR 22.67. The further course of weekend trading at Lang & Schwarz until 1:00 p.m. CEST is shown by the continuously updated real-time quote of GSK stock.

Market context: Market report FTSE 100.